Arcadia Biosciences (NASDAQ:RKDA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report issued on Tuesday morning. The brokerage issued a sell rating on the basic materials company’s stock.

Several other analysts have also issued reports on the company. Lake Street Capital upgraded Arcadia Biosciences to a strong-buy rating in a report on Tuesday, May 14th. HC Wainwright reaffirmed a buy rating and set a $6.00 price target on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Stock Up 2.3 %

NASDAQ:RKDA opened at $2.93 on Tuesday. Arcadia Biosciences has a twelve month low of $1.85 and a twelve month high of $4.79. The company has a market cap of $3.99 million, a P/E ratio of -0.57 and a beta of 0.86. The business has a 50 day moving average price of $2.92 and a two-hundred day moving average price of $2.67.

Arcadia Biosciences (NASDAQ:RKDA) last released its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. The business had revenue of $1.31 million during the quarter, compared to the consensus estimate of $0.95 million. During the same period last year, the business posted ($2.64) EPS. As a group, analysts anticipate that Arcadia Biosciences will post -2.29 earnings per share for the current fiscal year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.